Buying or backing a device company? Know what you're buying.
The financials show what a company earned. A technical review shows what it will cost to keep earning it: the architecture, the regulatory path, and the debt that surfaces after closing.
What we review.
A review follows the product from design to the field, and flags what a buyer would otherwise find in the first year.
- Architecture. Hardware and software structure, third-party components, and what is hard to change.
- Regulatory path. Clearances and approvals held, open commitments, and what the next submission will take.
- Design history. Whether the design file, risk file and usability evidence would survive an inspection or a deficiency letter.
- Software and cybersecurity. Open-source and third-party code, update capability, and change classification.
- Supply chain. Single-source parts, end-of-life components, and manufacturing transfer risk.
- Technical debt. Shortcuts that were cheap before closing and become expensive after it.
Who it is for.
Venture and growth investors, corporate development teams and strategic acquirers in medtech and pharma.
You get a written report your investment committee can read, with findings ranked by how much they matter to the deal. We work with your counsel and your other advisors, and we are comfortable in the room with the founders.
The review draws on twenty years of taking drug-delivery devices through FDA, CE and IND processes, and on engineering roles at companies that were acquired.